NEWS & EVENTS

The report is the third since Catalent launched its CR strategy to address a wide range of environmental, social, and governance (ESG) topics related to its business.

Catalent today announced that company experts will be speaking on current clinical market trends and strategies at two upcoming conferences: Clinical Trial Supply New England; and Clinical Trial Supply Europe.

TFF Pharmaceuticals and Catalent today announced their collaboration agreement focused on the generation, testing and manufacture of dry powder formulations for a range of biotherapeutics.

Catalent today announced that it plans to expand its Waigaoqiao Free Trade Zone (FTZ) facility in Shanghai, China, to increase capacity for temperature-controlled storage and distribution of clinical supplies.

Catalent today announced that it has been officially recognized by the Top Employers Institute as a Top Employer 2022 in both the United States and the United Kingdom.

Catalent today announced that it has completed a $10 million expansion at its Malvern, Pennsylvania, and Dartford, U.K., facilities, to provide advanced containment capabilities for the micronization of highly potent drug compounds.

Catalent today announced the launch of its new Xpress Pharmaceutics® service, designed to accelerate the development of oral drugs through Phase 1 clinical studies.

Catalent today announced that it has increased cold chain packaging capabilities at its Philadelphia facility to support increased demand for the distribution of biologic drugs, and advanced cell and gene therapies.

Catalent today announced that its Board of Directors has appointed Alessandro Maselli, currently President and Chief Operating Officer, as the company’s next President and Chief Executive Officer, effective July 1, 2022.